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Abstract
Cancer, a proliferative disease hallmarked by abnormal
cell growth and spread, is largely dependent on tumor
neoangiogenesis, with evidence of vascular endothelial
dysfunction. Novel ways to assess vascular function in
cancer include measuring levels of circulating endothe-
lial cells (CEC). Rare in healthy individuals, increased
CEC in peripheral blood reflects significant vascular
damage and dysfunction. They have been documented
in many human diseases, including different types of
cancers. An additional circulating cell population are en-
dothelial progenitor cells (EPC), which have the ability
to form endothelial colonies in vitro and may contribute
toward vasculogenesis. At present, there is great interest
in evaluating the role of EPC as novel markers for tumor
angiogenesis and drug therapy monitoring. Recently,
exocytic procoagulant endothelial microparticles (EMP)
have also been identified. CEC, EPC, and EMP research
works may have important clinical implications but are
often impeded by methodological issues and a lack of
consensus on phenotypic identification of these cells
and particles. This review aims to collate existing lit-
erature and provide an overview on the current position
of CEC, EPC, and EMP in cell biology terms and to iden-
tify their significance to clinical medicine, with particular
emphasis on relationship with cancer.
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Introduction
Recent research has established the importance of altered
vascular endothelium function to the neoplastic disease
process. Studies have shown that cancer progression is
largely dependent on abnormal angiogenesis, whereby new
vessel formation ensures an adequate supply of nutrients,
oxygen, and growth factors to the growing tumor and also
facilitates tumor dissemination [1]. Vascular endothelial cells
(EC) respond to numerous pathophysiological stimuli such
as growth factors, cytokines, lipoproteins, and oxidative
stress. Prolonged or unregulated activation of these cells
often results in a loss of EC integrity and, thus, dysfunction—a
process that can be assessed by the use of specific plasma
markers such as von Willebrand factor (vWf), tissue plasmino-
gen activator, soluble EC protein C receptor, soluble E selectin,
and soluble thrombomodulin, as well as physiological techniques
such as flow-mediated dilatation (FMD) [2]. Indeed, endothelial
perturbation in cancer may well contribute to an increased risk of
thrombosis in these patients [3].
The presence of circulating endothelial cells (CEC) has
recently been recognized as a useful marker of vascular
damage. Usually absent in the blood of healthy individuals,
CEC counts are elevated in diseases hallmarked by the pres-
ence of vascular insult, such as sickle cell anemia, acute
myocardial infarction, Cytomegalovirus (CMV) infection, endo-
toxemia, and neoplastic processes. Current opinion suggests
that CEC are cells driven from the intima after vascular insult,
and are thus the consequence—rather than the initiator—of
a particular pathology [4].
A related circulating cell population are endothelial progenitor
cells (EPC), which originate from the bone marrow, rather than
from vessel walls. Seen in small numbers in healthy individuals,
their numbers tend to increase following vascular injury [5]. So
far, experiments have established the ability of EPC to form colo-
nies in vitro, suggesting a role in both angiogenesis and in the
maintenance of existing vessel walls [6]. Recent evidence has
suggested the involvement of EPC in tumor vasculogenesis [7].
Recently, another endothelial marker linked with vascular
dysfunction has been identified. Endothelial microparticles
(EMP) are vesicles formed by the EC membrane after injury
or activation, harboring cell surface proteins and cytoplasmic
elements and expressing endothelial-specific surface markers
reflective of parent cell status (e.g., activated, apoptotic) [8].
Due to the diversity of techniques found in CEC, EPC, and
EMP research, it is often difficult to compare data between
different investigating groups, frequently leading to confusion.
The main objectives of this review article are: 1) to collate
existing literature; 2) to provide an overview of the current
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position of these cells and particles in cell biology terms; and
3) to identify its significance in clinical medicine, with partic-
ular emphasis on relationship with cancer.
Search Strategy
We conducted a literature search using Medline, PubMed,
and EMBASE to highlight published works with keywords
CEC, EPC, EMP, vascular injury, angiogenesis, and cancer.
Results were limited to articles published between 1980 and
2005 in English peer-reviewed journals. Abstracts and re-
ports frommeetings were included only when they related di-
rectly to previously published works.
CEC
Background CEC were first described in the 1970s using
methods such as light microscopy, cell morphology, May
Gru¨nwald Giemsa staining, and density centrifugation. None
of these methods identified CEC conclusively due to lack
of endothelium-specific antibody markers; moreover, the
methods were generally too cumbersome.
In 1991, monoclonal antibodies to two new cell surface an-
tigens specific to EC (HEC 19 and S-Endo 1) were reported,
allowing for a more accurate quantification of CEC [9]. George
et al. named the antigen for their S-Endo 1 antibody CD146.
Solovey et al. [10] subsequently used another antibodyP1H12
against CD146 to enumerate CEC in sickle cell anemia.
Mancuso et al. [11] were the first to describe CEC in cancer.
Enumeration Despite the lack of a clear consensus on
phenotypic identification, CEC are generally accepted as
cells expressing endothelial markers [e.g., vWf, CD146,
and vascular endothelial cadherin (VE-cadherin)] in the ab-
sence of hematopoietic (CD45 and CD14) and progenitor
(CD133) markers. Interestingly, the progenitor marker CD34
is also present on mature CEC. Although CD146 is widely
regarded as the principal marker for CEC (mature cell form), it
has also been described in trophoblasts, mesenchymal stem
cells, periodontal and malignant (prostatic cancer and mela-
noma) tissues [4], and activated lymphocytes [12]. Conse-
quently, caution in interpreting results with CD146 alone is
demanded as cells identified by this marker may indeed be
circulating tumor cells or other non-endothelial circulating
cell. As such, it may be advisable to use a second identifica-
tion method, such as Ulex europaeus lectin-1 (UEA-1),
acetylated low-density lipoprotein cholesterol, or vWf.
Together with EPC, CEC only represent between 0.01%
and 0.0001% of mononuclear cells in normal peripheral blood
[12], making it very difficult to accurately quantify their numb-
ers. To do this, it is often necessary to employ cell enrichment
techniques combined with specific cell marker labeling.
The immunobead capture method (immunomagnetic
beads bearing CD146 antibodies) developed by George et al.
[9] is the most widely used. Immunobeads have been suc-
cessfully employed by other investigators, albeit with modifi-
cations [e.g., addition of EDTA and albumin to minimize CEC
autoaggregation; drying CEC on a glass slide before counting
(this enables storage at room temperature and secondary
labeling); use of UEA-1 (an EC-specific stain); addition of an
Fc receptor blocking agent, and double labeling for further
analyses (e.g., for CD31 andCD34)] [4]. After cell separation,
either fluorescence microscopy (Figure 1), immunocyto-
chemistry, or flow cytometry is used to confirm the endothelial
phenotype of the cells. Other methods used to concentrate
mononuclear cell suspensions include standard and density
(Lymphoprep, Axis-Shield, Oslo, Norway; Percoll, Sigma, St.
Louis, MO; Ficoll, Sigma) centrifugation and mononuclear
cell culturing on fibronectin-coated plates. [4]. Themain alter-
native to the immunobead method is flow cytometry [11,12].
In current published literature, the reported numbers of
CEC vary significantly from 1 to 39,000 cells/ml in disease
states, and from 0 to 7900 cells/ml in healthy controls. The
variation in numbers stems partly from the diverse nature
of the diseases investigated, but also from the nonstandard-
ization of the methods used. For example, immunobead and
density centrifugation methods tend to show values of
around 10 cells/ml in healthy controls, whereas the numbers
yielded by flow cytometry are much greater (up to a 1000-fold
increase) [4,11]. The reasons for this discrepancy are unclear
but would appear methodological [i.e., technical (gating) and/
or different choices of cell surface markers to define CEC]
[12]. Accordingly, consensus is badly needed.
Owing to significant differences in CEC enumeration de-
pending on the technique used, a comparison of meaningful
data between investigating groups is difficult. As such, the
optimal method for CEC quantification remains unknown,
with more research needed on correlative functional and ge-
nomic studies of separated cells to measure the accuracy of
immunophenotyping [4].
Origin and pathophysiology of CEC The endothelium can
be viewed as a membrane-like layer lining the circulatory
system, its primary function being the maintenance of vessel
wall permeability and integrity. The EC layer is relatively
quiescent, with an estimated cell turnover period of between
47 and 23,000 days, as shown by labeling studies [13].
Proliferation seems to occur mainly at sites of vasculature
branching and turbulent flow. As mentioned before, CEC
Figure 1. Fluorescence microscopy of a large CEC rosetted by immuno-
beads.
80 Circulating Endothelial Cells Goon et al.
Neoplasia . Vol. 8, No. 2, 2006
are thought to have ‘‘sloughed off’’ vessel walls, indicating
severe endothelial damage [4] (Figure 2). Thus, unsurpris-
ingly, CEC have been shown to correlate with various
endothelial dysfunction and inflammatory markers (Refs.
[14–19]; Table 1).
Although not fully understood, it would appear that CEC
detachment from the endothelium involves multiple factors,
such as mechanical injury, alteration of endothelial cellular
adhesion molecules (such as integrin aVb3), defective bind-
ing to anchoring matrix proteins (such as fibronectin, laminin,
or type IV collagen), and cellular apoptosis with decreased
survival of cytoskeletal proteins [4,20]. The net effect is a re-
duced interaction between the EC and basement membrane
proteins, with subsequent cellular detachment.
Depending on the disease process, it would seem that
the vessel origin of CEC can vary significantly. Researchers
using specific antibody markers were able to delineate the
microvascular (CD36) origin of CEC in diseases such as
cancer, thalassemia, and sickle cell disease (SCD) [10,11,21].
Conversely, CEC in acute coronary syndrome and systemic
lupus erythematosus (SLE) patients were from the macro-
vasculature [4,22]. In short, by analyzing the phenotypic
expression of CEC, important knowledge on the severity and
pathogenesis of vascular diseases can be obtained in a rela-
tively noninvasive manner.
CEC in cancer Elevated numbers of CEC have been
variously described in lymphoma, melanoma, and glioma
patients, as well as in breast, colonic, gastric, esophageal,
renal cell, ovarian, cervical, carcinoid, testicular, prostate,
and head and neck cancer patients, reflecting the perturba-
tion of vascular endothelium in cancer disease (Refs.
[11,23–26]; Table 2). However, the clinical significance of
CEC in cancer is still poorly understood; we do not know
whether or not CEC are merely markers of altered vascular
integrity, or are direct contributors to the neoplastic process
and its associated complications. Particularly significant is
the way in which CEC appear in the circulation of cancer
patients. Are the CEC being shed from localized damaged
or activated tumor vessels, or from a more generalized
Figure 2. Potential mechanisms for EC detachment and microparticle formation. CEC, circulating endothelial cells; EMP, endothelial microparticles; sTM, soluble
thrombomodulin; sE-Sel, soluble E-selectin; vWF, von Willebrand factor.
Table 1. Correlation of CEC with Markers of Inflammation and Endothelial Dysfunction.
References Disease Marker/Measurement of Vascular Damage Correlation with CEC Count
q (r ) P
Chong et al. [14] CHF FMD 0.423 <.002
vWf 0.29 .032
Del Papa et al. [15] Systemic sclerosis sE-Sel 0.594 .01
Kas-Deelen et al. [16] CMV vWf _* <.001
Lee et al. [17] ACS IL-6 0.55 <.001
vWf 0.44 <.001
Makin et al. [18] Atherosclerotic disease vWf 0.40 <.002
TF 0.296 <.021
Rajagopalan et al. [19] SLE FMD 0.32 <.037
TF 0.46 <.002
CHF, congestive heart failure; ACS, acute coronary syndromes; sE-Sel, soluble E-selectin.
*Data not provided.
Circulating Endothelial Cells Goon et al. 81
Neoplasia . Vol. 8, No. 2, 2006
systemic endothelial activation? Are they cells that have
originated from bone marrow progenitor cells differentiating
into mature CEC form?
Recently, Mancuso et al. [11], using cytometric analysis,
demonstrated a five-fold increase (P < .0008) of CEC in
breast cancer (n = 46) and lymphoma (n = 30) patients
compared with healthy controls (n = 20). In this study, CEC
levels in early and metastatic (advanced stage) breast
cancer patients were not significantly different, whereas
quadrantectomy (breast-conserving surgery) was associ-
ated with a reduction in CEC. In addition, lymphoma patients
with total disease remission after chemotherapy (n = 7)
achieved normal levels of CEC, therefore suggesting a
potential role for CEC in monitoring response to anticancer
treatment [11]. Beerepoot et al. [23,24] also found a signifi-
cant rise in CEC in cancer patients with progressive disease
(n = 95; P < .001), whereas patients with stable disease (n =
17; P < .69) yielded levels comparable to healthy controls.
Different methods of assessing disease stage were
employed in these studies. For example, Beerepoot et al.
[23] defined ‘‘progressive disease’’ as a radiologic increase
in tumor size, but Mancuso et al. [11] employed node and
metastatic status. In addition, the immunobead method
was employed by Beerepoot et al., whereas Mancuso et al.
used flow cytometry; this clearly precludes a direct compar-
ison of results between the two investigating groups.
Zhang et al. [26] characterized CEC in multiple myeloma
(MM), reporting elevated numbers of both CEC (P < .001)
and EPC. CEC also correlated well with serum markers
of disease activity, namely, serum M protein and b2-
microglobulin (r = 0.62, P < .001; r = 0.72, P < .001,
respectively). They also demonstrated a clinical response
to treatment with thalidomide and its immunoregulatory
derivative CC-5013, indicated by a parallel decline in both
CEC and EPC levels with disease activity. This makes CEC/
EPC measurements a potentially useful indicator of re-
sponse to treatment in MM.
However, a serious confounder in clinical studies is the
role of chemotherapy and radiotherapy. Indeed, it has been
established that a certain cytotoxic chemotherapy is spe-
cifically designed to attack the endothelium and, as such,
endothelial damagemay well be a side effect of other chemo-
therapies [27,28]. Accordingly, as does raised plasma vWf
[29], raised CEC may well reflect treatment but not neces-
sarily the oncologic process.
Association of CEC with other markers in cancer As a
surrogate marker of angiogenesis, it is not surprising to note
that vascular endothelial growth factor (VEGF) has a strong
associationwithmalignant disease [7,30]. In cancer, increased
VEGF released from tumor cells, as well as macrophages
and platelets [31], is associated with tumor progression
and poor prognosis [32]. Indeed, Mancuso et al. [11] demon-
strated a positive correlation between CEC and both VEGF
(r = 0.42, P = .009) and vascular adhesion molecule-1 (r =
0.582, P < .0001) in breast cancer patients. Their findings
may imply a relationship with angiogenesis. In contrast,
Beerepoot et al. [23] showedno suchcorrelation (CEC versus
VEGF) in their study subjects (n = 95) and postulated a num-
ber of reasons for this, such as the limited half-life of plasma
cytokines and the possible variations between local and
systemic levels.
Other studies also note that CEC viability appears mark-
edly pronounced in tumor-bearing models versus controls
[33]. Because VEGF is a mitogen and a survival factor for
EC [7] possessing antiapoptotic properties, it is conceiv-
able that it has a protective role in preventing CEC apopto-
sis [34]. Beerepoot et al. [23] also investigated the possible
association of other cytokines [placental growth factor
(PlGF), stromal-derived factor-1 (SDF-1), and stem cell fac-
tor (SCF)] with CEC and found increased PGF levels in
cancer patients (P = .01). SDF-1 and SCF levels were no
different between patients and controls.
Recently, interest has risen in the assessment of the
endothelial-specific adhesion molecule VE-cadherin (cad-
herin-5 or CD144) specifically in the context of tumor angio-
genesis [35]. Martin et al. [36] established a positive
relationship between levels of VE-cadherin and microvessel
density (MVD) in breast cancer specimens, relating in-
creased VE-cadherin RNA with poorer prognosis, posi-
tive node status, and higher TNM staging. Furthermore,
Rabascio et al. [37] reported elevated levels of VE-cadherin
RNA expression in cancer patients (P < .001) compared to
controls, suggesting a novel technique in assessing cancer
angiogenesis. Importantly, they demonstrated a significant
correlation between VE-cadherin RNA and viable CEC in
patients with hematologic malignancies (r = 0.86, P = .008).
The clinical significance is unclear because VE-cadherin
is important for cell-to-cell interactions and the integrity of
the cellular monolayer [38,39]; an increase in its expres-
sion should likewise reflect a stable vascular endothelium,
Table 2. Studies in Human Cancer Patients and the Relationship with CEC and EPC.
References Method Cancer Type Number of Patients Mean CEC Number (ml) Mean EPC Number (ml)
Controls Patients Controls Patients
Beerepoot et al. [23] IB Variety* 95 121 ± 16 399 ± 36 NA NA
Beerepoot et al. [24] IB Variety* 34 82 ± 25 157 ± 27 NA NA
Kim et al. [25] Culture + IC* Gastric, breast 71 NA NA 40.2 ± 10.2y 37.6 ± 4.2y
Mancuso et al. [11] FC Breast, lymphoma 76 7900 39,000 <500 <500
Zhang et al. [26] FC MM 31 <10003 >7,500z NA NA
IB, immunobead; IC, immunocytochemistry; FC, flow cytometry
*A variety of cancers: head and neck, colon, prostate, gastric, esophagus, renal, breast, ovarian, cervix, and carcinoid cancers, as well as melanoma and glioma.
yStated per unit area (mm2).
zRaw data not supplied; estimated from figures in the text.
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resulting in an expected decrease in CEC. In reality, the
loss of VE-cadherin expression actually results in the dis-
assembly of nascent blood vessels in murine models [40].
Further studies are warranted to establish a similar positive
association in solid tumors.
CEC and coagulopathy Thrombosis is a big problem in
cancer [3]. Tissue factor (TF), the primary cellular initiator of
blood coagulation in vivo, is associated with both systemic
hypercoagulability [41] and tumor angiogenesis in cancer
[42]. Secreted by tumor cells [43], TF upregulation contrib-
utes to tumor progression and correlates with clinical stage,
histologic grade, and poor prognosis [44,45], although direct
inhibition of TF suppresses tumor growth [46]. To date, the
only demonstrable positive correlation between CEC and
circulating TF has been in diseases with vascular damage/
dysfunction, such as atherosclerotic diseases [18], SLE [19],
and sickle cell anemia [10]. In cancer, despite clear TF ex-
pression on malignant tumor EC [47], there is a distinct lack
of any similar exression on CEC, as described by Beerepoot
et al. [24]. The reason for this is unclear, as in vitro stimulation
of CEC induced TF expression. To explain this conundrum, the
authors speculate that local intratumoral coagulation [48]
results in a ‘‘sump’’ for TF-positive CEC and prevents these
CEC from appearing in the peripheral circulation. Of note, this
has not been validated in any experiment to date.
EPC
Background and methodology Asahara et al. [49] was the
first to isolate EPC in human peripheral blood, using anti-
CD34monoclonal antibodies. With the use of CD133, an anti-
gen specifically identifying primitive stem cells, a novel means
to precisely delineatemature (CEC) from immature (EPC) EC
forms was possible [50], although this antigen is only present
in human EPC and cannot be applied to mouse EPC [51]. To
detect EPC in peripheral blood, flow cytometry and culture
have become the principalmethods employed.Othermarkers
used include vWf, VE-cadherin, vascular endothelial growth
factor receptor-2 (VEGFR-KDR) and binding by lectins and
acetylated low-density lipoproteins [50–52].
Origin and pathophysiology of EPC EPC are potentially
crucial for neovascularization and may be recruited from
the bone marrow after tissue ischemia, vascular insult, or
tumor growth [5,51–53]. They possess the ability to migrate,
colonize, proliferate, and, ultimately, differentiate into endo-
thelial lineage cells. These cells have yet to acquire mature
EC characteristics (Figure 3) while appearing to contribute
to vascular homeostasis.
EPC have been isolated previously from human umbilical
cord blood, adult bone marrow, human fetal liver cells, and
cytokine-mobilized peripheral blood, and an increase in cir-
culating EPC follows in vivo administration of the angiogenic
Figure 3. Schematic representation of CEC, EPC, and HSC in vascular damage, repair, and angiogenesis. EMP, endothelial microparticles; VEGF, vascular
endothelial growth factor; KDR, VEGFR-2.
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growth factor VEGF [52,53]. When incubated with VEGF,
fibroblast growth factor-2 (FGF-2), and insulin-like growth
factor, CD133+ cells differentiated into mature-type adherent
EC, expressing endothelial-specific cell markers (vWf and VE-
cadherin) and abolishing CD133 expression [54]. For example,
Lin et al. [55] documented the generation of endothelial out-
growths that are positive for CD146, vWf (mature endothelial
markers), and CD36 (a microvascular marker) markers from
circulating mononuclear cells (of donor genotype in bone
marrow transplant patients), which strongly suggests the
viability and proliferative potential of EPC.
EPC recruitment and mobilization have been positively
correlated with increased levels of angiogenic growth fac-
tors such as VEGF [56]. VEGF induces the proliferation,
differentiation, and chemotaxis of EPC, and is essential for
hematopoiesis, angiogenesis, and, ultimately, survival, as evi-
denced by the nonviability of mouse embryos expressing only
a single VEGF allele [57]. EPC influence cells mainly by
interactions with VEGFR-1 and VEGFR-2, both being re-
ceptors expressed on hematopoietic stem cells (HSC) and
EPC (Figure 3) [58]. In another study, granulocyte colony-
stimulating factor also increased the number of CD34+ cells,
potentially stimulating neovascularization in areas of is-
chemic myocardium [59]. Other angiogenic growth factors
stimulating EPC mobilization include angiopoietin-1, FGF,
SDF-1, PlGF, and (in mice) macrophage colony-stimulating
factor [60–64]. After mobilization, EPC appear to ‘‘home in’’
and become incorporated into sites of vascular injury and
ischemia, with evidence of improvement in the function and
viability of tissue (e.g., after acute myocardial infarction) [59].
Chemotactic agents responsible for this process include
VEGF [65] and SDF-1 [62], but others may also be involved.
In the clinical setting, moderate exercise of patients with
stable coronary artery diseases leads to a significant in-
crease in circulating EPC [66]. Furthermore, EPC and HSC
introduced into the circulation of acute and chronic cardio-
vascular disease patients through injection have shown
encouraging preliminary results, with evidence of improved
cardiovascular function and tissue perfusion [67]; as yet,
there are no randomized control trials.
Cancer, Neovascularization, and EPC: More Questions
than Answers?
Blood vessels are essentially composed of EC that align
and interconnect, forming tubes for directing and maintain-
ing blood flow. In cancer, new blood vessel formation is
essential for its growth and dissemination. The traditionally
accepted view is that neovascularization in adult life occurs
by a process known as angiogenesis [68], whereby new
capillaries sprout from existing vasculature as vessel wall–
associated EC proliferate and migrate. New research has
suggested an alternative means by which vessels are
formed, namely, by postnatal vasculogenesis or by differen-
tiation of primitive/progenitor EC into mature EC [49]. These
cells originate from the bone marrow cell population, with
subsequent mobilization and homing to sites of vascular
growth and repair [68].
More controversially, in cancer, do EPC mobilize in re-
sponse to cytokine release either by tumor cells or from
damaged tissues/host immune cells? If so, do EPC merely
perform a regulatory role in angiogenesis, or do they form
part of the new tumor vasculature? The current evidence
for BM-derived EC neoincorporation into tumor vasculature
is conflicting. In some studies, it has been shown that bone
marrow–derived EPC contribute to tumor vessel formation
by incorporating into the neoendothelium [53,68]. In mice
transplantation studies, donor BM-derived EC integrated into
newly formed blood vessels, sometimes by as much as 50%
[69], whereas other studies reported lower but significant
levels between 10% and 20% [51,70]. These findings have
recently been challenged by the work of De Palma et al.
[71], who demonstrated BM-derived hemopoietic cells
(CD45+/CD11b+/CD31/Tie2+) rather than EPC (CD31+),
homed specifically to tumors, without any evidence of in-
corporation. The reason for such diametrically conflicting re-
sults remains unclear. The reason might be the use of
differing experimental models and techniques to identify
BM-derived endothelium [72]. Despite the controversy, De
Palma et al. [71] demonstrated that inhibition of the BM-
derived Tie2-expressing mononuclear cells with a ‘‘suicide’’
gene approach resulted in a significant reduction of tumor
angiogenesis and growth. The implications may herald new
targets for novel antitumor treatment [72].
Several other reports, some based on laser scanning
confocal microscopy techniques (i.e., a more definitive cell
detection method), have also questioned the importance and
veracity of the ‘‘neointegration’’ concept and, instead, have
implicated other hematopoietic BM-derived cells such as
monocytes, macrophages, or pericyte precursors [73,74].
These cells are felt to be angiogenesis-promoting and ad-
here to vessel walls without actual integration. Indeed,
Shaked et al. [75] strongly correlated peripheral blood
CD13+/VEGFR-2+/CD45/CD117+ cells (defining them as
EPC) with angiogenesis but did not directly address this
contentious issue. Instead, they concluded that there are
measurable circulating VEGFR-2+ cells contributing to an-
giogenesis, which might be true endothelial ‘‘progenitor’’ cells
or perivascular adherent ‘‘support’’ cells; these constitute a
valid surrogate marker for angiogenesis, particularly when
assessing antiangiogenesis therapy.
As mentioned, VEGF-induced BM-derived EPC mobiliza-
tion has been reported [61,68]. However, in human cancer
patients, Mancuso et al. [11] noted no significant rise in EPC
levels as compared with healthy controls, even with raised
levels of VEGF. This finding was recently corroborated by Kim
et al. [25] and suggests that typical VEGF levels in cancer
patients might not be sufficient to mobilize EPC into the
circulation (Table 3). In another study, Zhang et al. [26] (men-
tioned earlier) reported raised EPC levels in MM patients.
CEC and EPC: Surrogate Markers of Tumor
Angiogenesis and Growth?
Because the role of tumor angiogenesis is seen as crucial
in the progression of cancer, attempts have beenmade to ac-
curately measure this process [e.g., relative MVD estimates
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(Chalkley count method), EC proliferation fractions, and
VEGF levels] [76]. Currently, measurements of tumor angio-
genesis aimed at evaluating antiangiogenic cancer therapy
are based mainly on MVD; in this technique, blood vessels in
tumor samples are stained with relevant endothelial anti-
bodies and counted through light microscopy. However, it is
labor-intensive and requires tissues that could potentially be
unrepresentative of the whole tumor.
Animal models bearing human lymphoma show a corre-
lation of CEC levels with tumor growth/volume and suggest
its use as a potential surrogate marker of angiogenesis
[32–34]. Mice xenografted with human lymphoma also show
higher values of CEC compared with controls. CEC and tu-
mor volume correlate strongly (r = 0.942, P = .004), com-
pared with standard MVD measurements (MVD versus
tumor volume: r = 0.948, P = .05). In addition, CEC correlated
positively with tumor weight (r = 0.885, P = .01) and tumor-
generated human VEGF (r = 0.669, P = .02).
In the same model, administration of cyclophosphamide
(CTX) was investigated using maximum tolerable dose
(MTD) and metronomic regimens. MTD provoked a vigorous
EPC elevation in peripheral blood, in stark contrast to
metronomic CTX, which suppressed EPC numbers and via-
bility (increased apoptosis) with concurrent tumor inhibition.
MTD CTX induced the apoptosis of circulating hematopoi-
etic and, to a lesser extent, of CEC. The authors suggest a
mechanism of direct cell death by CTX and, possibly, inhibi-
tion of EPC mobilization, causing an antivasculogenetic ef-
fect to explain the results of metronomic chemotherapy [77].
In parallel studies, continuous endostatin infusion (CEI)
was compared with bolus administration. Compared with
bolus chemotherapy, CEI treatment caused greater inhibition
as well as differentiation of EPC, with significant tumor
(human lymphoma) suppression. Unlike CTX, endostatin
seemed to target cells of endothelial, rather than hemato-
poietic, lineage [33]. Schuch et al. [78] reported a reduction in
EPC numbers along with decreased bone marrow neovas-
cularization in mice receiving endostatin. Furthermore, endo-
statin was shown to target EPC mobilization (in the presence
of VEGF stimulation) and increased the rate of apoptosis,
thus confirming the findings of Capillo et al. [33]. Preliminary
reports of phase 1 clinical trials with endostatin highlighted a
>10-fold CEC reduction in patients with stable lymphoma
disease, compared with no change or an increase in pro-
gressive disease patients [79].
Another report [75] demonstrated a strong correlation
between tumor growth and both CEC and EPC numbers in
mice using various tumor models [transplanted versus spon-
taneous, solid versus leukemic; syngeneic Lewis lung carci-
noma LL/2, erythroleukemia, orthotopic human breast
cancer MDA-MB-231, and human lymphoma (Namalwa)]
and was able to effectively define the optimal antiangiogenic
drug (anti–VEGFR-2) dosage based on CEC and EPCmoni-
toring. Their results are all the more significant as they were
based on different tumor types, antiangiogenic drugs, and
mouse strains. In a recent phase 1 trial, VEGF-specific anti-
body bevacizumab (Avastin) reduced tumor MVD, tumor per-
fusion and vascular volume, interstitial fluid pressure, and
the number of viable CEC and EPC in rectal carcinoma pa-
tients (P < .05, Wilcoxon signed rank), indicating that VEGF
blockade has a direct antivascular effect on human tumors in
the clinical setting [80].
These reports are especially encouraging as they suggest
the potential of peripheral blood CEC/EPC evaluation to
monitor antiangiogenic therapy efficacy and also help define
the balance between cytotoxic and therapeutic thresholds of
various drug regimes. This method of assessment would be
a significant advantage compared with current methods
(e.g., MVD or dynamic contrast-enhanced magnetic reso-
nance imaging) [30].
EMP
One of the earliest descriptions of EMP was the shedding
of membrane-derived particles from human umbilical vein
endothelial cells (HUVEC) after complement-mediated lysis
[81]. Combes et al. [82] subsequently induced EMP for-
mation after the activation of HUVEC with TNF-a and also
by the incubation of EC with the serum from antiphospholipid
syndrome patients. Elevated EMP levels have since been
demonstrated in a variety of diseases [83–91], but, as
yet, there have been no adequately powered case–control
studies in cancer.
Origin and enumeration The main cellular mechanisms
known to induce EMP release from the endothelium are
cellular activation, damage, and apoptosis [83] (Figure 2).
EMP formation has been demonstrated using in vitro EC
activation by cytokines such as TNF-a and interleukin (IL) 1
[83]. Laurence et al. [84] further reported apoptotic cell
changes in EC after exposure to TTP plasma, suggesting a
Table 3. Differences Between CEC, EPC, and EMP.
Plasma Marker CEC EPC EMP
Origin Mature endothelium Bone marrow, cord blood, mobilized MC EC
Morphology Mature cells 20–50 mM in diameter Immature cells <20 mM in diameter Exocytic vesicles 0.5–1.5 mM in diameter
Phenotype CD133 ve /CD146 +ve CD133 +ve/CD34 +ve/KDR + CD146 ve Endothelial markers*
High proliferative potential No Yes No




*Dependent on the status of parent cell (i.e., activated, apoptotic).
yCauses monocyte activation and endothelial damage (reproduced with permission and adapted from Ref. [92]).
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potential correlation of EMP elevation with apoptosis. The
phenotypic profile of EMP can vary considerably, depending
on whether parent cells have undergone either activation
(abundant CD62E+) or apoptosis (predominantly CD31+)
[83]. The commonest technique used to identify EMP is high
relative centrifugal force (RCF) in conjunction with flow cytom-
etry [82]. Less well known is the solid phase capture method
[85]. Unfortunately, EMP identification by these methods also
lends itself to significant variations in the numbers obtained,
possibly due to variations in technique—a situation reminis-
cent of CEC.
Pathophysiology Although their significance remains un-
clear, there is a growing view that EMP can function as im-
portant diffusible mediators of cytokines and adhesins, thus
promoting cellular signaling and activity [86]. In vitro stimu-
lation of HUVEC by angiogenic growth factors (VEGF and
FGF-2) resulted in EMP formation that is rich in matrix metal-
loproteins and capillary cord–like structures, suggesting a
potential in vivo role in angiogenesis [87].
It has been shown that EMP have procoagulant activity,
defined by platelet factor 3 activity and TF [88]. In pro-
thrombotic states such as SCD, Shet et al. [89] reported
raised TF-positive EMP in patients compared with controls,
and a strong correlation with procoagulant activity. Of note,
Jimenez et al. [90] reported severe endothelial dysfunction
in mice aorta after incubation with EMP, affecting the endo-
thelial nitric oxide (NO) transduction pathway, but not NO
synthase expression. EMP may also be proinflammatory
as they tend to bind and activate monocytes, resulting in
cytokine release (e.g., TNF-a and IL-1b), which causes
further paracrine and/or autocrine activation of monocytes
and endothelium [91].
These studies raise the possibility of EMPbeingmediators
of vascular insult and inflammation in diseases, rather than
just being markers of endothelial dysfunction. More data are
required to answer these issues, particularly in its relationship
with cancer, of which there are currently no reports to the best
of our knowledge. These lead to the speculation of raised
EMP in cancer and, possibly, to the hypothesis that they may
have a role in the coagulopathy of this disease.
Conclusions and Future Directions
CEC elevation in the blood of patients is becoming estab-
lished as a useful marker for severe vascular dysfunction
[92]. The presence of CEC in significant numbers denotes
a high degree of vascular damage and, in this respect, ismore
useful as a clinical marker than, for example, raised vWf or
abnormal FMD. The significance of CEC elevation in cancer
patients is less clear. Certainly, CEC reflect loss of vascular
integrity to some degree (e.g., in the case of necrotic tumors
or in postchemotherapy tumors) [11]. What is less clear is the
functional contribution, if any, of CEC toward tumor angio-
genesis. From existing research data, it is apparent that EPC
have a potentially significant role to play in the evaluation of
tumor angiogenesis and growth [93]. Mobilization by growth
factors [56,59–65] and other agents such as statins [94] may
reflect a new therapy. However, to clearly elucidate the
biology of CEC, EPC, and EMP in cancer, more research is
essential. Current efforts are hampered, in part, by the lack of
a clear consensus on phenotypic definitions, which has led to
much difficulty in comparing data. Indeed, this lack of precise
definition has surely contributed to conflict.
Recent reports suggest that CEC and EPC enumera-
tion can be used to monitor antiangiogenesis drug therapy,
with some success. This exciting prospect needs to be fully
corroborated in a clinical setting. In addition, CEC and EPC
monitoring would need to be efficient, specific, robust, and
reproducible. Therefore, it is vital to reach a general consen-
sus regarding definitions and techniques for CEC, EPC, and
EMP quantification, in order to validate further reports that
have implications for future clinical trials involving these
markers. Further study of CEC and EPC may represent a
vital source of information in the understanding of tumor
biology and would potentially be an important evaluator of
tumor growth and angiogenesis, as well as a means of
monitoring antiangiogenic drug activity.
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